Death receptors can directly (type I cells) or indirectly induce apoptosis by activating mitochondrial-regulated apoptosis (type II cells). The level of caspase 8 activation is thought to determine whether a cell is type I or II, with type II cells less efficient at activating this caspase following death receptor activation. FLICE-inhibitory protein (FLIP) blocks death receptor-mediated apoptosis by inhibiting caspase 8 activation; therefore, we assessed whether silencing FLIP could convert type II cells into type I. FLIP silencing-induced caspase 8 activation in Bax wild-type and null HCT116 colorectal cancer cells; however, complete caspase 3 processing and apoptosis were only observed in Bax wild-type cells. Bax-null cells were also more resistant to chemotherapy and tumor necrosis factor-related apoptosis inducing ligand and, unlike the Bax wild-type cells, were not sensitized to these agents by FLIP silencing. Further analyses indicated that release of second mitochondrial activator of caspases from mitochondria and subsequent inhibition of X-linked inhibitor of apoptosis protein (XIAP) was required to induce full caspase 3 processing and apoptosis following FLIP silencing. These results indicate that silencing FLIP does not necessarily bypass the requirement for mitochondrial involvement in type II cells. Furthermore, targeting FLIP and XIAP may represent a therapeutic strategy for the treatment of colorectal tumors with defects in mitochondrial-regulated apoptosis.
Introduction
Death receptors, such as Fas (CD95) and the tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptors, TRAIL-R1 (DR4) or TRAIL-R2 (DR5) are activated by Fas ligand and TRAIL respectively (Ashkenazi and Dixit, 1998) . Activated death receptors recruit Fas-associated death domain (FADD) . FADD, in turn, recruits procaspase 8 (FADD-like interleukin-1b converting enzyme, FLICE) into a death-inducing signaling complex, at which caspase 8 is activated (Kischkel et al., 1995) . However, caspase 8 activation at the death-inducing signaling complex can be inhibited by FLICE-inhibitory protein (FLIP) (Scaffidi et al., 1999) .
Cells are classified as type I or type II with regard to death receptor-mediated apoptosis (Scaffidi et al., 1998) . Following death receptor ligation, type I cells can fully activate executioner caspases (such as caspase 3) and induce apoptosis, whereas, in type II cells, engagement of the intrinsic mitochondrial-regulated apoptosis is required. Cross-talk between the extrinsic and intrinsic apoptotic pathways is mediated by Bid, which, when cleaved by caspase 8, translocates to the mitochondria and promotes Bax-and Bak-mediated release of proapoptotic factors , including cytochrome c and second mitochondrial activator of caspases (Smac). In the cytosol, cytochrome c forms a complex with caspase 9 known as the apoptosome (Zou et al., 1999) . Smac/Diablo directly antagonizes the inhibitors of apoptosis proteins (IAPs) . IAPs such as X-linked IAP (XIAP) inhibit the activity of caspases, thereby blocking apoptosis (Bratton and Cohen, 2003) . Caspases 8 and 9 can cleave the procaspase form of caspase 3 to generate p19 and p12 subunits, which form a catalytically active heterotetrameric complex. XIAP inhibits caspase 3 activation by binding to the p19-p12 caspase 3 complex through its BIR2 domain. In addition, XIAP can inhibit caspase 9 activation through its BIR3 domain (Deveraux and Reed, 1999) . However, autocatalytic cleavage of the p19 caspase 3 subunit to a p17-form results in removal of the XIAP-binding site and attenuates XIAP-mediated inhibition of caspase 3.
One factor thought to determine whether a cell is type I or II is caspase 8 activation, with type II cells less efficient at activating this apical caspase following death receptor ligation (Scaffidi et al., 1998) . We have shown previously that FLIP gene silencing can induce apoptosis in colorectal cancer cells and sensitize them to TRAIL-and chemotherapy-induced apoptosis (Longley et al., 2006; Wilson et al., 2007) . It has been suggested that chemotherapy-induced DR5 upregulation sensitizes type II colorectal cancer cells to TRAIL when mito-chondrial-mediated apoptosis is blocked by converting them into type I cells (Wang and El-Deiry, 2003) . The initial aim of this study was to investigate whether FLIP silencing could similarly bypass the requirement for mitochondrial involvement in death receptor-mediated apoptosis in type II cells by enhancing caspase 8 activation thereby converting them into type I cells.
Results
Bax-null cells are resistant to apoptosis induced by FLIP silencing Expression of pro-and anti-apoptotic proteins was assessed in a panel of colorectal cancer cell lines: HCT116 parental; HCT116 Bax heterozygous (Bax þ /À ); HCT116 Bax deficient (Bax À/À ); H630 and HT29 ( Figure 1a ). All cell lines expressed similar levels of FLIP L and FLIP S . The HCT116 cell lines expressed similar levels of Bcl-2, Bcl-X L , Mcl-1 and XIAP. Bax expression was equivalent in the HCT116 parental and Bax heterozygous cells. As expected, Bax was not detected in the HCT116 Bax-null cell line. The H630 cell line had relatively high levels of Bak and Bid expression and particularly high Bcl-2 expression. The HT29 cell line had slightly elevated Bcl-X L , but very low levels of Bcl-2 and Mcl-1. In addition, XIAP expression was lower in HT29 cells compared with the other lines.
To characterize the role of Bax in regulating apoptosis induced by FLIP-targeted siRNA, we compared the HCT116 Bax wild-type and Bax-null cell lines. HCT116 cells have been characterized as type II with respect to death receptor-mediated apoptosis (Ozoren and El-Deiry, 2002) . Treatment of HCT116 Bax wild-type cells with 10 nM FLIP siRNA induced caspase 8, 3 and 9 activation and cell death (as indicated by PARP cleavage) compared with a non-silencing control siR-NA; however, no cell death was observed in the HCT116 Bax-null cell line (Figure 1b) . Identical results were obtained using two further FLIP-targeted (FT) siRNAs, including a modified FT siRNA duplex (Stealth RNAi, Invitrogen, Paisley, UK) that eliminates sense strand off-target effects and non-specific stress responses (Supplementary Figure 1a) . Furthermore, similar results were obtained when FT siRNA was transfected by electroporation: PARP cleavage was observed in the Bax wild-type cell line, but not the Bax-null cell line, and cell viability and colony formation were significantly more inhibited in the Bax wildtype cell line following FLIP silencing than in the Bax-null cell line (Supplementary Figure 1b) . It was noted that, treatment with FLIP siRNA induced full activation of caspase 8 in the HCT116 Bax-null cell line, whereas processing of caspase 3 to its p17-form was not detected (Figure 1b) . Furthermore, no activation of caspase 9 was observed in the Bax-null cells following FLIP silencing. These results were confirmed using flow cytometry, as we found that, in contrast to the Bax-expressing HCT116 cell line, the Bax-null cell line did not undergo apoptosis following FLIP silencing ( Figure 1c ).
FLIP silencing fails to sensitize Bax-null cells to TRAIL and chemotherapy
We have demonstrated previously that FLIP silencing can sensitize HCT116 parental cells to apoptosis induced by death ligands such as TRAIL and the Fas agonistic antibody CH-11 (Galligan et al., 2005; Longley et al., 2006) . As shown by PARP cleavage and the percentage of cells in the apoptotic sub-G0/G1 fraction, HCT116 Bax wild-type cells were sensitive to TRAIL treatment, and the extent of apoptosis induced by TRAIL was further enhanced following transfection of FLIP siRNA (Figures 2a and b) . However, HCT116 Bax-null cells were resistant to TRAIL treatment, both in the presence and absence of FLIP siRNA. Similar results were obtained with CH-11, indicating that Bax is also important in regulating Fas-mediated apoptosis in HCT116 cells (Figure 2b ). Similar to treatment with FLIP siRNA as a single agent, full caspase 8 activation was observed in the FLIP siRNA and TRAIL co-treated Bax-null cells, but the p17-form of caspase 3 was not observed, and caspase 9 was not activated (Figure 2a) . Collectively, these results suggest that despite facilitating caspase 8 activation, FLIP silencing does not necessarily bypass the requirement for Bax and mitochondrial involvement in death receptor-mediated apoptosis in type II cells.
We reported previously that FLIP silencing sensitized colorectal cancer cells to chemotherapy (Longley et al., 2006) , and we, therefore, tested whether FLIP silencing could sensitize HCT116 Bax-null cells to chemotherapyinduced apoptosis. HCT116 Bax wild-type cells that were transfected with FLIP siRNA exhibited enhanced sensitivity to chemotherapy (5-fluorouracil, oxaliplatin and irinotecan), as demonstrated by increased caspase 8, 3 and 9 activation and PARP cleavage (Figure 2c) . However, the HCT116 Bax-null cells were highly resistant to combined FLIP siRNA and chemotherapy co-treatment, despite significant caspase 8 activation. Again, no caspase 9 activation was observed in FLIP siRNA and chemotherapy co-treated Bax-null cells, and cleavage of caspase 3 to the p17-form was not observed.
SN38-resistant cells are Bax null and are cross-resistant to FLIP siRNA and TRAIL We recently developed a HCT116 daughter cell line that is resistant to the active metabolite of irinotecan, SN38. HCT116 cells were treated with stepwise increasing concentrations of SN38, resulting in a cell line with an IC50 dose >20-fold higher than the parental cell line (>100 versus 5 nM). Comparison of this SN38-resistant daughter cell line with the parental line indicated that it expressed similar levels of XIAP, but slightly higher levels of FLIP L , FLIP S , Bcl-X L and Bcl-2 ( Figure 3a) . Interestingly, we found that the SN38-resistant cell line had lost Bax expression. Despite expressing similar levels of DR4 and DR5 as the parental cell line (data not shown), the HCT116 SN38-resistant cell line was highly resistant to TRAIL-induced apoptosis ( Figure 3b ). Flow cytometry analysis indicated that the HCT116 SN38-resistant cell line was not sensitive to FLIP siRNA, either as a single agent or when combined with TRAIL ( Figure 3c ). To confirm that the inhibition of apoptosis was due to incomplete processing of caspase 3, HCT116 parental and SN38-resistant cells were transfected with FLIP siRNA and co-treated with TRAIL or SN38 as indicated. HCT116 parental cells were sensitized to TRAIL and SN38 following FLIP silencing ( Figure 3d ). Despite activating caspase 8, albeit to a lesser extent than parental cells, the SN38 daughter cell line was not significantly sensitized to TRAIL or SN38 by FLIP silencing. Importantly, full caspase 3 processing to its p17-form was inhibited in the SN38-resistant cells. These results indicate that cells that have lost Bax expression through an acquired drug resistant mechanism behave similarly to the HCT116 Bax-null cell line with respect to its sensitivity to TRAIL and FLIP silencing.
Requirement for Bid in apoptosis induction following FLIP silencing
We further investigated the role of the mitochondria in regulating FLIP siRNA-induced apoptosis by silencing Bid and caspase 9. In HCT116 parental cells transfected with FLIP siRNA, full-length Bid expression was decreased ( Figure 4a , lane 1 compared with lane 3), suggesting that Bid may be processed and mediate cross-talk between caspase 8 and the intrinsic apoptotic pathway following FLIP silencing. In support of this, transfection of parental HCT116 cells with Bid siRNA attenuated cell death induced by FLIP silencing (Figures  4a and b) . Decreasing Bid expression reduced but did not block caspase 8 activation following FLIP silencing. However, activation of caspase 9 was completely abrogated and the p17-form of caspase 3 was not observed in cells lacking Bid. Similar results were observed in the HT29 cell line (Figure 4c ). However, silencing Bid failed to rescue apoptosis induced by FLIP siRNA in the H630 cell line (Figure 4c ), suggesting that Bid-mediated cross-talk with the mitochondria is not required to induce apoptosis in this cell line.
Caspase 9 is not required for apoptosis induction following FLIP silencing As shown in Figure 5a , FLIP silencing promoted the release of cytochrome c from the mitochondria into the cytosol in HCT116 Bax wild-type cells (Figure 5a ). Furthermore, this release was dramatically attenuated in the Bax-null cell line. To directly examine the involvement of caspase 9 in inducing apoptosis following FLIP silencing, we used caspase 9-specific siRNAs. Transfection of HCT116 parental cells with three different caspase 9-targeted siRNAs significantly decreased the expression of procasapse 9 and inhibited baseline and TRAIL-induced caspase 9 activity (Figure 4d ). In cells transfected with caspase 9 siRNAs, active caspase 9 (p35) was not observed following FLIP silencing; however, this did not inhibit PARP cleavage or processing of caspase 3 to its p17-form (Figure 4e ). Caspase 9-targeted siRNA also failed to significantly rescue H630 and HT29 cells from the effects of FLIP siRNA (Figure 4f ). These results suggest that caspase 9 activity may not be required for FLIP siRNA-induced apoptosis, despite the fact that FLIP silencing promotes the release of cytochrome c from the mitochondria.
XIAP inhibits apoptosis induction following FLIP silencing
We next assessed whether the release of other proapoptotic proteins from the mitochondria was involved in inducing apoptosis following FLIP silencing. We found that Smac was released from the mitochondria into the cytoplasm in HCT116 Bax wild-type, but not in Bax-null cells following FLIP silencing (Figure 5a ). To assess the importance of Smac, we decreased Smac expression in the HCT116 parental cell line using Smactargeted siRNAs. Decreasing Smac expression abrogated FLIP siRNA-induced PARP cleavage in HCT116 parental cells (Figure 5b) . Furthermore, co-treatment of Bax-null cells with FLIP siRNA and a Smac peptide mimetic enhanced caspase 8 activation and induced cell death as indicated by PARP cleavage (Figure 5c ). These results suggest that release of Smac with subsequent inhibition of IAP(s) is important for cell death induced by FLIP silencing. The most potent member of the IAP family is the XIAP (Deveraux and Reed, 1999) . It was noted that, the Smac peptide mimetic decreased XIAP expression in Bax-null cells, particularly in cells cotreated with FLIP siRNA (Figure 5c ). This suggested that XIAP could be a key regulator of FLIP siRNAinduced cell death in these cells. To formally assess this, we transfected HCT116 Bax wild-type and Bax-null cells with XIAP-targeted siRNAs for 24 h, prior to transfection with FLIP or non-silencing control siRNAs. XIAP silencing moderately enhanced FLIP siRNA-induced cell death in the HCT116 Bax wild-type cells as indicated by PARP cleavage and flow cytometry (Figures 5d and e) . Most significantly, in the HCT116 Bax-null cell line, XIAP and FLIP co-silencing induced full caspase 3 processing to its p17-form and cell death as demonstrated by PARP cleavage (Figure 5d ). Similar results were observed with two further XIAP-targeting siRNAs (Supplementary Figure 1c) . Analysis of the apoptotic sub-G0/G1 population of cells by flow cytometry indicated that the induction of apoptosis by combined treatment with FLIP and XIAP siRNAs was supra-additive in HCT116 Bax-null cells (Figure 5e , P ¼ 0.014). Furthermore, the levels of apoptosis in Bax-null cells co-transfected with the FLIP and XIAP siRNAs were similar to the levels induced by FLIP siRNA alone in the Bax wild-type cell line, suggesting that XIAP is indeed a key determinant of apoptosis induced following FLIP silencing.
To determine whether FLIP and XIAP co-silencing could sensitize HCT116 Bax-null cells to TRAILinduced apoptosis, we transfected HCT116 Bax-null cells with XIAP-and FLIP-targeted siRNAs and cotreated with TRAIL. Analysis of the Annexin V-positive cells indicated that XIAP silencing resulted in greater sensitization of the Bax-null cells to TRAIL-induced apoptosis than FLIP silencing (Figure 5f ). However, combined silencing of FLIP and XIAP resulted in the greatest induction of apoptosis following TRAIL treatment (Figure 5f ). Collectively, these results suggest that for apoptosis to occur following FLIP silencing, Smac release from the mitochondria is required to alleviate XIAP-mediated inhibition of p19-p12 caspase 3. In addition, an increase in activated caspase 9 was observed following co-treatment of Bax-null cells with FLIP and XIAP siRNAs (Figure 5d ). This suggests that, although caspase 9 may not be absolutely required for the induction of apoptosis (Figure 4d ), XIAP may also inhibit its activation in response to FLIP silencing.
Discussion
The role of FLIP as a key regulator of death ligandinduced apoptosis is well established (Yeh et al., 2000; Mathas et al., 2004) . We have demonstrated previously that silencing FLIP induces apoptosis in a panel of colorectal cancer cell lines in a manner that is dependent on caspase 8 and DR5, but that appears to be independent of DR5 ligation by TRAIL (Wilson et al., 2007) . Furthermore, we found that injecting FLIP Cells were re-transfected 24 h later with 1 nM SC or FT siRNA and co-treated with 5 ng/ml TRAIL for a further 24 h. The statistical significance of differences in apoptosis were calculated using two-way ANOVA; * represents the difference between SC, FT, XT and FT þ XT groups (Po0.05); # represents the difference between SC, SC þ TRAIL, XT and XT þ TRAIL groups (Po0.05); a represents the difference between SC, SC þ TRAIL, FT and FT þ TRAIL groups (P ¼ 0.03); b represents the difference between SC, SC þ TRAIL, FT þ XT and FT þ XT þ TRAIL groups (P ¼ 0.007). TRAIL, tumor necrosis factor-related apoptosis inducing ligand; Smac, second mitochondrial activator of caspases; ANOVA, analysis of variance.
siRNA into xenografts retarded the growth of colorectal cancer cells in vivo. In addition, we found that FLIP promotes resistance to chemotherapy, as FLIP gene silencing enhanced chemotherapy-induced cell death in vitro, and FLIP L overexpression conferred resistance to chemotherapeutic agents both in vitro and in vivo (Longley et al., 2006; Wilson et al., 2007) . We and others have found that FLIP overexpression renders cells resistant to death ligands (Jonsson et al., 2003; Longley et al., 2006) , whereas FLIP downregulation increases sensitivity (Yeh et al., 2000; Mathas et al., 2004; Galligan et al., 2005; Longley et al., 2006) . Cell lines are classified as type I or II depending on whether they require mitochondrial involvement to induce apoptosis following death receptor activation. One of the factors thought to determine whether a cell is type I or II is the efficiency with which caspase 8 activation is coupled to death receptor ligation (Scaffidi et al., 1998) .
The initial aim of this study was to investigate whether FLIP downregulation could convert type II cells into type I cells by enhancing death receptormediated activation of caspase 8. Earlier studies have demonstrated that the HCT116 cell line is type II with respect to death receptor-mediated apoptosis (Ozoren and El-Deiry, 2002) . So, we utilized HCT116 Bax wildtype and null isogenic cell lines to test our hypothesis. Earlier characterisation of HCT116 cell lines indicated that cells lacking Bax are resistant to TRAIL and are significantly less sensitive to chemotherapy (Zhang et al., 2000; Arango et al., 2004) . In contrast to Bax wild-type colorectal cancer cell lines, we found that FLIP silencing did not induce cell death in HCT116 cells lacking Bax. Moreover, FLIP silencing did not sensitize Bax-null cells to treatment with TRAIL or chemotherapy. Interestingly, similar levels of caspase 8 activation were observed in both Bax wild-type and null cell lines following FLIP silencing (both alone and in the presence of chemotherapy or TRAIL); however, full cleavage of caspase 3 (p17-form) and activation of caspase 9 were not observed in the cells lacking Bax. Thus, FLIP silencing with concomitant increases in caspase 8 activation is not necessarily sufficient to convert a type II cell into a type I cell.
Several studies in HCT116 and other cell line models have indicated that Bak cannot compensate for loss of Bax to induce apoptosis in response to TRAIL (LeBlanc et al., 2002; Theodorakis et al., 2002; Han et al., 2004; von Haefen et al., 2004) . HCT116 Bax-null cells express similar levels of Bak as the parental cells (Figure 1a) , and Bak has been shown to be functional in HCT116 Bax-null cells (Theodorakis et al., 2002) . Thus, our data suggest that Bak is also unable to compensate for loss of Bax in the induction of apoptosis following FLIP silencing. An earlier study suggested that chemotherapy treatment converted HCT116 Bax-null cells into type I cells by upregulating DR5 expression; thereby, enhancing TRAIL-induced death-inducing signaling complex formation (Wang and El-Deiry, 2003) . However, our FLIP siRNA data suggest that it is not possible to convert type II HCT116 cells into type I cells by simply enhancing caspase 8 activation. Furthermore, we failed earlier to observe any changes in TRAIL receptor expression at the cell surface in HCT116 cells following chemotherapy treatment (Galligan et al., 2005) . It may be that the chemotherapy-induced sensitization of Baxnull HCT116 cells to TRAIL observed by Wang and El-Deiry was due to the downstream effects of the chemotherapy rather than DR5-proximal effects.
The BH3 family member Bid mediates the cross-talk between the extrinsic and intrinsic apoptotic pathways . Earlier studies have shown that the overexpression of a dominant negative Bid construct inhibited apoptosis induced by both the Fas and TRAIL receptors in Jurkat cells (Werner et al., 2002) , and Bid has been reported to regulate the synergy between TRAIL and epotoside in M28 and REN cells (Broaddus et al., 2005) . We found that Bid is critical for FLIP silencing-induced processing of caspase 3 and cell death in the HCT116 and HT29 cells, indicating that mitochondrial activation is required for cell death to occur. In contrast, Bid was not required for FLIP siRNA-induced cell death in H630 cells, suggesting that these cells behave like type I cells following FLIP silencing.
Depolarisation of mitochondrial membrane potential and release of pro-apoptotic molecules, such as cytochrome c and Smac, into the cytosol is a critical step during mitochondrial-regulated apoptosis (Kroemer and Reed, 2000) . We found that Smac and cytochrome c were released into the cytosol following FLIP silencing in HCT116 cells expressing Bax; however, this release was attenuated in the Bax-null cell line. Release of cytochrome c induces the activation of caspase 9. Embryonic stem cells or fibroblasts derived from caspase 9 knockout mice demonstrated a critical role for caspase 9 in inducing cell death in response to DNA damaging agents (Wang, 2001) . Other studies have demonstrated that the caspase 9 inhibitor Z-LEHD-FMK (fluoromethylketone) prevented TRAIL-induced apoptosis in HCT116 cells (Ozoren et al., 2000; Kim et al., 2004) . However, the selectivity of FMK-based small molecule caspase inhibitors (especially Z-LEHD-FMK) is highly debatable (Berger et al., 2006) . We found that inhibiting caspase 9 activity using a more specific siRNA strategy failed to rescue apoptosis induced by FLIP siRNA in our panel of CRC cell lines. This is in agreement with a study by Deng et al., who demonstrated that transfection of a caspase 9-dominant negative construct did not prevent TRAIL-induced apoptosis in HCT116 cells (Deng et al., 2002) .
Smac disrupts the interaction between the BIR3 domain of XIAP and caspase 9, and the interaction between the linker-BIR2 domain of XIAP and caspases 3 and 7, thereby alleviating XIAP-mediated caspase inhibition (Chai et al., 2000) . Jurkat T cells overexpressing Smac have been shown to be more sensitive to epothilone B and TRAIL treatment (Guo et al., 2002) . Earlier studies have shown that resistance to TRAIL in HCT116 Bax-null cells can be reversed by overexpression of Smac (Deng et al., 2002) . We found that siRNAs targeting Smac inhibited the apoptosis induced by FLIP silencing in HCT116 parental cells.
Furthermore, we found that a Smac peptide mimetic sensitized HCT116 Bax-null cells to FLIP silencing, and this coincided with decreased XIAP expression. XIAP has been shown to be the most potent member of the IAP family and to regulate the response of cancer cell lines to chemotherapy and radiotherapy in vitro (Dean et al., 2007) . Increased expression of XIAP has been observed in many human cancers, including prostate, lung and acute/chronic leukemia (Ferreira et al., 2001; Krajewska et al., 2003; Schimmer et al., 2003) . Furthermore, its expression has been correlated with a worse prognosis in bladder carcinoma, renal cell carcinoma and acute myloid leukemia (Tamm et al., 2004; Li et al., 2007; Mizutani et al., 2007) . Earlier studies have shown that HCT116 or DLD-1 cells in which XIAP expression has been downregulated exhibit increased caspase 3 cleavage and apoptosis in response to TRAIL (Cummins et al., 2004) . Sun et al. demonstrated that XIAP overexpression prevented the full processing of caspase 3 to the p17-form following Fas ligand treatment, an observation that was reversed with the addition of Smac . Importantly, we found that siRNA targeting XIAP synergistically sensitized HCT116 Bax-null cells to FLIP silencing, an observation that coincided with full caspase 3 processing to its p17-form. Furthermore, caspase 9 activation was observed in Bax-null cells co-treated with FLIP and XIAP siRNAs (Figure 5d ). Thus, although caspase 9 is not required for the induction of apoptosis, it appears that XIAP also inhibits its activation in response to FLIP silencing. The activation of caspase 9 following combined FLIP and XIAP silencing may not only be due to alleviation of direct XIAP-mediated repression of caspase 9, but also to caspase 3-mediated activation of caspase 9 in a feedback amplification loop: once active, caspase 3 can cleave the N-terminal region of caspase 9 that interacts with XIAP and also cleave and inactivate XIAP itself (Slee et al., 1999; Ekert and Silke, 2001) . Similarly, the enhanced caspase 8 activation observed in Bax-null cells co-treated with FLIP and XIAP siRNAs (Figure 5d ) is likely to be due to caspase 3-mediated activation of a feedback amplification loop, possibly involving caspase 6 (Slee et al., 1999) . These results suggest that although FLIP silencing can induce spontaneous caspase 8 activation, apoptosis is not necessarily induced unless XIAP-mediated inhibition of caspase 3 is alleviated.
FLIP has been found to be overexpressed in many human cancers (Ryu et al., 2001; Zhou et al., 2004; Valnet-Rabier et al., 2005) , and has emerged through our work and that of others, as a potential anti-cancer drug target (Hyer et al., 2005; Wilson et al., 2007) . Furthermore, XIAP has been found to be overexpressed in several cancers, and small molecule and antisense approaches to target XIAP are in development (Hu et al., 2003; LaCasse et al., 2006) . In addition, dysfunctional mitochondrial-mediated apoptosis, for example due to Bcl-2 or Bcl-X L overexpression (Adams and Cory, 2007; Verdine and Walensky, 2007) or loss of Bax expression (Jansson and Sun, 2002; Kang et al., 2007 ) is a common occurrence in human cancers. Our results suggest that simultaneously targeting both FLIP and XIAP may prove useful in the treatment of cancers, particularly those in which the intrinsic mitochondrial apoptotic pathway has been compromised. However, further work is necessary to assess the relative toxicity of targeting FLIP and XIAP in normal and cancer cells.
Materials and methods

Reagents
The Smac-N7 peptide was purchased from Calbiochem (Darmstadt, Germany). TRAIL was purchased from Calbiochem (San Diego, CA, USA). The Fas agonistic antibody (CH-11) was purchased from MBL (Worburn, MA, USA). Annexin V was purchased from BD Biosciences (Franklin Lakes, NJ, USA).
Cell culture
All cells were maintained in 5% CO 2 at 37 1C. H630 and HT29 cells were maintained in Dulbecco's modified Eagle's medium with 10% bovine calf serum supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine and 50 mg/ml penicillin/streptomycin (all from Invitrogen). HCT116 parental, HCT116 Bax þ /À and HCT116 Bax À/À isogenic human colorectal cancer cells were kindly provided by Professor Bert Vogelstein (John Hopkins University, Baltimore, MD, USA). All HCT116 cell lines were grown in McCoy's 5A medium (Invitrogen) supplemented with 10% dialysed fetal calf serum, 50 mg/ml penicillin-streptomycin, 2 mM L-glutamine and 1 mM sodium pyruvate.
Western blotting
Western blots were performed as described earlier (Longley et al., 2006) . Caspase 8 (Alexis Biochemicals, Birmingham, UK), PARP (eBioscience, San Diego, CA), Smac (Cell Signaling Technology, Danvers, MA, USA) and FLIP (NF-6, Alexis Biochemicals) mouse monoclonal antibodies were used in conjunction with a horseradish peroxidase-conjugated sheep anti-mouse secondary antibody (Amersham, Little Chalfont, Buckinghamshire, England). Caspase 9, caspase 3, Bcl-2, Bcl-X L , Bak, Bax, Bid, XIAP (all from Cell Signaling Technology) and Mcl-1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) rabbit antibodies were used in conjunction with a horseradish peroxidase-conjugated donkey anti-rabbit secondary antibody (Amersham). Equal loading was assessed using a b-tubulin mouse monoclonal primary antibody (Sigma, Poole, Dorset, UK).
Flow cytometry DNA content of cells was evaluated by propidium iodide staining of cells using the EPICS XL Flow Cytometer (Coulter, Miami, FL, USA). Apoptosis was determined by evaluating the percentage of cells with DNA content o2N. For Annexin V/PI analysis, cells were harvested and analysed according to manufacturer's instructions (BD Biosciences).
siRNA transfections FLIP-targeted and the non-silencing control siRNAs (Dharmacon, Lafayette, CO, USA) were described earlier (Wilson et al., 2007) . Pre-designed siRNAs were purchased for Bid (SMARTpool, Dharmacon), XIAP (Cell Signaling Technology), caspase 9 (Qiagen, Germantown, MD, USA and Imgenex, San Diego, CA, USA) and Smac (Qiagen). siRNA transfections were performed using Oligofectamine reagent (Invitrogen) according to the manufacturer's instructions.
